Post-anaesthetic advice imparted to breastfeeding mothers can vary. This is due in part to the differing information from published data, product information sheets and inevitably from the unhindered flow of opinions available on the internet. This literature review examined the evidence relating to drugs commonly used in the modern anaesthetic setting and their impact on breastfed children. It suggests that special precautions are rarely warranted in the post-anaesthetic care of breastfeeding patients.
In the field of obstetric anaesthesia, the placental transfer of drugs is a shared and incontrovertible focus for both anaesthetic and neonatal clinicians. However, opinions about anaesthetic drug transfer via breastmilk are far from uniform. Data on the transfer of anaesthetic and analgesic drugs into breastmilk are somewhat limited due to the difficulties in recruiting nursing mothers and neonates for controlled studies. Consequently, advice on matters such as milk discards, feed delays or whether precautions are needed can vary depending on which hospital or medically-endorsed guideline is sought. In addition, objective evidence relevant to this subject may be cumbersome for clinicians to sift through and practically impossible for the public to clearly decipher. Much of the information published by pharmaceutical companies consists of generic warnings, with wording more akin to legal disclaimers than authoritative medical advice. For these reasons we have compiled a tabulated summary of the current evidence for drugs used in anaesthetic practice and their impact on children via breastmilk.
METHODS
Anaesthetic drugs and commonly used adjuvants were identified from our departmental formulary and sub-classified into the standard categories of inhalational anaesthetics; premedication and induction drugs; neuromuscular blocking and reversal drugs; opioids; local anaesthetics; non-opioid analgesics; anticoagulants; anti-emetics; antibiotics; and other. Advanced resuscitative drugs (e.g. adrenaline or dantrolene) were not considered due to the nonelective nature of their use.
A literature search was conducted for each of the drugs stocked for perioperative use at our hospital (48 in total) using the Medline, PubMed and Embase databases as search tools. Keywords such as 'anaesthesia', 'breastfeeding mothers', 'breastmilk transfer' and 'neonates' were used. The bulk of data retrieved originated from case reports or series (Level 4 evidence based on levels of evidence used by the Centre for Evidence Based Medicine 1 ) for example articles by Stuttman et al 2 on remifentanil and xenon, and Madadi et al 3 on codeine. The search did not identify any systematic reviews of cohort studies (Level 2a) and only a handful of articles of Level 2 evidence, since studies involving breastfeeding mothers and neonates were scarce. Notable studies include limited controlled trials by Wilson et al 4 Fifty-two of the 54 references identified (96%) were published in the period from 1990-2012. With respect to the context of breastfeeding, a small number of well-established drugs had not appeared in the published literature for several decades. The two older articles referred to neostigmine (Fraser and Turner 7 , 1963) and metronidazole (Passmore et al 8 , 1988) .
Commercial formularies, such as the Monthly Index of Medical Specialties, were also consulted to locate referenced articles but were not used as primary sources of data. The findings were then tabulated according to the classes of action and the relative safety of each drug.
RESULTS
Current evidence suggests that breastfeeding need not be interrupted nor modified following a standard anaesthetic 9, 10 . General measures are recommended to minimise the impact of surgery and anaesthesia on lactation and feeding patterns. These general measures include: feeding as close to the pre-anaesthetic period as possible; expressing and storing breastmilk for later use when the mother is in surgery and recovery; and adequate hydration (especially intravenous hydration during the fasting period and providing an additional 500-1000 ml for fluid loss associated with breastfeeding 11 ).
All drugs commonly used in the anaesthetic setting have long been used on lactating patients. Reports of serious reactions are rare and contraindications are relative in otherwise healthy mothers and term babies. Awareness of the following findings will help minimise adverse outcomes.
Drugs with no milk transfer or safety verified by targeted studies
The scope of drugs available for modern general and regional anaesthesia is wide enough that direct adverse impact on the nursing mother or infant can be avoided. By virtue of their chemistry (e.g. large, polarised neuromuscular blocker 12 or local anaesthetic molecules) or their pharmacokinetics (e.g. rapid elimination of volatile anaesthetics), many of the commonly used drugs do not cross into lactating ducts in any meaningful quantities, if at all. This is certainly true for warfarin, a drug required by some obstetric patients, because its polarity and its 99% bond to albumin render it undetectable in breastmilk. When specifically tested in breastfed infants, no alteration was demonstrated on their coagulation profiles 13 .
Metoclopramide has been used to promote lactation in breastfeeding mothers and no adverse impact on infants has been reported [14] [15] [16] . Xenon 2 and neostigmine 7 are undetectable in human breastmilk after their administration to lactating mothers. Heparin does not cross into breastmilk 17 , while glycopyrrolate 18 , nitrous oxide 18 and isoflurane 12 have negligible transfer. Thiopentone 12 , propofol 12, 19 , midazolam 19 , enoxaparin 20 , lignocaine 21 , bupivacaine 21, 22 , ropivacaine 22 , fentanyl 12, 19 , tramadol 23 and paracetamol 12, 24 are all excreted in human breastmilk in doses that are too low to be clinically significant.
Although high-dose labour epidural fentanyl (>150 µg) was found to be associated with a higher incidence of bottle feeding at six weeks postpartum, there was no detectable effect on initiation of breastfeeding 4, 5 or on neonatal respiration 25 . Conversely, adjuvant epidural fentanyl has been demonstrated to improve patient satisfaction, reduce local anaesthetic usage and consequent motor blockade 5 . Further studies are required before concluding whether or not epidural fentanyl has lasting ill-effects on neonates. Similarly, the safety of epidural pethidine in the patient-controlled epidural analgesia mode was also verified when the levels of both pethidine and norpethidine were consistently subclinical in targeted measurements 26 .
For drugs that are known to be detectable in breastmilk, many were still found to be safe for the nursing infant. These include metronidazole 8 , ampicillin 27 and gentamicin 28 , all of which have been classified by the American Academy of Pediatrics as compatible with breastfeeding 29 .
In the case of nonsteroidal anti-inflammatory drugs, only aspirin 29 recorded an adverse impact on nursing infants. All other nonsteroidal antiinflammatory drugs were detected in human breastmilk in concentrations that were too low to affect neonates 24 . Likewise, single doses of parecoxib (and hence valdecoxib) were detectable in breastmilk after caesarean deliveries without a demonstrable effect on neonates 30 .
The amount of nicotine passed into human breastmilk via a transdermal patch varies according to the patch's strength, but manifests in concentrations lower than those from smoking. The use of nicotine patches does not affect the milk intake of breastfed infants 31 .
Drugs known to have potential or mild impact in infants
Droperidol has been used to prevent and treat maternal nausea and vomiting associated with morphine patient-controlled analgesia after caesarean delivery, and a decrease in neurological status in the breastfed infants has been observed 32 . The clinical significance of this has not been elucidated.
Caffeine, sometimes prescribed for lactating mothers who suffer from post-dural puncture headache, has been shown to have little to no effect on the breastfed infant after occasional use 33 . Nevertheless, it would seem advisable to restrict caffeine consumption to less than 300 mg/day due to the risk of depleting the iron content of breastmilk 34 . There are also reports of irritability in breastfed infants after maternal consumption of high doses 33 .
Morphine 12, 24, 35 , pethidine 12, 24 and methadone 36 are all known to be excreted in human breastmilk. No studies to date have shown an adverse impact on the breastfed infant of mothers receiving methadone 36 , low or single doses of morphine 12, 24, 35 and epidural 26 or single doses of pethidine 24 . Larger and repeated maternal doses of intravenous pethidine, however, did produce signs of neurobehavioural depression 12, 24 in breastfed neonates. Amongst the pethidine cohort, neonates of mothers using comparable doses of patient-controlled intravenous pethidine (4.7 mg/ kg) or morphine (0.54 mg/kg) in the first 48 hours postpartum demonstrated lower levels of alertness and orientation on day three of life 37 . For women with chronic opioid use throughout pregnancy, particularly methadone, breastfeeding is recommended, but gradual weaning is warranted to avoid neonatal opioid withdrawal 38 .
Drugs known to have caused serious adverse effects in infants
Although short-term use of diazepam was thought to be compatible with breastfeeding 39, 40 , diazepam has also been demonstrated to cause sedation and feeding difficulties 41 in some breastfed infants. In the modern era, abundant alternatives are available as substitutes for diazepam 42 . Likewise in the case of aspirin, where a case of infantile metabolic acidosis has been described 29 , a myriad of alternative nonsteroidal antiinflammatory drugs that safely meet the pharmacological needs of the mother are available.
The variability of maternal metabolism of codeine to morphine, in combination with the neonate's immature metabolism, was implicated in the death of one breastfed infant whose mother was prescribed codeine 43 . High levels of morphine were detected in this infant, due to maternal ultra-rapid metabolism of codeine to morphine. The frequency of this CYP2D6 genotype for 'ultra-rapid' metabolism is 1-7% amongst Caucasians, just a little less than the 10% of Caucasians who possess the 'slow' metabolising genotype 44 . Although doubts have been cast on the accuracy of this initial claim 45 , further studies have revealed central nervous system depression in breastfed neonates as a result of codeine administration to the mother 3, 46 . These effects have only been detected in the infant after four days of maternal codeine administration 47 .
Oxycodone shares the same cytochrome pathway of metabolism, and oxymorphone is one of its active metabolites 48 . Conflicting evidence exists about the safety profile of oxycodone in nursing infants. One study supported the long safety record of oxycodone for post-caesarean analgesia after measuring the milk and plasma concentrations of mothers and neonates. This study concluded that the amount ingested by a newborn is negligible 49 . Conversely, a recent retrospective survey revealed a level of neonatal sedation comparable to that seen when mothers use codeine 6 .
No human data
There is a group of drugs for which studies to detect presence in breastmilk have not been conducted. These generally fall into one of two categories: those that are well-established in practice following years of use (e.g. succinylcholine, atropine 50 , ketamine, sevoflurane 51 , desflurane 51 , remifentanil 2 , alfentanil 12,51 , ondansetron, prochlorperazine, vancomycin and cephalothin 51 ) or drugs relatively new to the market (e.g. dexmedetomidine, sugammadex). A minor exception to this categorisation is dexamethasone. Although specific human data are absent, an extensive history of other corticosteroids being used maternally in the perinatal period has yielded no evidence of neonatal effects via breastmilk 52 .
For these drugs, there are only original product information pamphlets stating that human data is not available. Clinical use, despite the absence of data, may be justified for older drugs based on the absence of adverse case reports among breastfed infants, especially if the drug is also approved for paediatric use.
CONCLUSION
The conclusions drawn are limited by the scarcity of large or robust studies evaluating the transfer of a number of perioperative drugs into breastmilk. Adequate recruitment of subjects is challenging due to the scarcity of breastfeeding women in need of surgical and anaesthetic services beyond the perinatal period. Furthermore, consent for phase II drug trials is unappealing to new mothers, especially if invasive tests on their newborns are required. Nevertheless, current evidence suggests that once the postoperative mother is alert and comfortable to do so, breastfeeding can and should resume with minimal interruption 9 . Commonsense measures are recommended to minimise the impact an anaesthetic has on breastfeeding 11 . A standard, one-off exposure to general and/or regional anaesthetic drugs should not be viewed as an impediment to breastfeeding. Conversely, the judicious use of adequate analgesia for postoperative mothers should not be compromised for the sake of breastfeeding. Drugs such as diazepam and codeine should be avoided if possible. A case also exists to extend breastfeeding studies and measurements for children beyond the neonatal age, where an increased amount of milk consumption, and hence the overall drug ingestion, may show a different pharmacodynamic profile. A summary of the safety profiles of the drugs evaluated in this study is provided in Table 1 . Pethidine (single dose) 12, 24 Pethidine (epidural) 26 Local anaesthetic agents Gentamicin (single dose) 28, 29 Other Nicotine patch 31 -Caffeine 33,34 --NSAID=nonsteroidal anti-inflammatory drugs.
